In an unusual deal, Bridge Biotherapeutics has become the first South Korean bioventure to be acquired by a global bitcoin treasury firm.
Parataxis Holdings, through Parataxis Korea Fund I and affiliates, announced it had reached a definitive agreement to invest KRW25bn ($18m)...